×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAZZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
04:18 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/17
04:15 pm
jazz
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16
05:49 pm
jazz
Jazz to search for new chief as CEO plans retirement [Yahoo! Finance]
Low
Report
Jazz to search for new chief as CEO plans retirement [Yahoo! Finance]
12/16
04:13 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan [Yahoo! Finance]
12/16
04:05 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan
12/16
04:05 pm
jazz
Jazz Pharmaceuticals Announces CEO Succession Plan
Low
Report
Jazz Pharmaceuticals Announces CEO Succession Plan
12/12
01:07 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
8.3%
jazz pharmaceuticals plc - ordinary shares
7/31/2024
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
3.7%
jazz pharmaceuticals plc - ordinary shares
5/1/2024
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-0.9%
jazz pharmaceuticals plc - ordinary shares
2/28/2024
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-8.2%
jazz pharmaceuticals plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
04:44 pm
jazz
Form 8-K Jazz Pharmaceuticals For: Dec 11
Low
Report
Form 8-K Jazz Pharmaceuticals For: Dec 11
12/9
06:45 pm
jazz
Form 4 Jazz Pharmaceuticals For: Dec 05 Filed by: GALA RENEE D
Low
Report
Form 4 Jazz Pharmaceuticals For: Dec 05 Filed by: GALA RENEE D
12/4
05:25 pm
jazz
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: COZADD BRUCE C
Low
Report
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: COZADD BRUCE C
12/4
05:23 pm
jazz
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: Carr Patricia
Low
Report
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: Carr Patricia
12/2
06:06 pm
jazz
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
Medium
Report
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
12/2
04:20 pm
jazz
Form 144 Jazz Pharmaceuticals Filed by: Carr Patricia
Low
Report
Form 144 Jazz Pharmaceuticals Filed by: Carr Patricia
11/26
05:08 pm
jazz
Form 8-K Jazz Pharmaceuticals For: Nov 26
Low
Report
Form 8-K Jazz Pharmaceuticals For: Nov 26
11/21
06:06 am
jazz
Form 8-K Jazz Pharmaceuticals For: Nov 20
Low
Report
Form 8-K Jazz Pharmaceuticals For: Nov 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat
9.3%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
TOP News Decliners
3/13
Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK
-11.3%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: